Business Context and Reporting Period
This Form 8-K Current Report was filed by Ultragenyx Pharmaceutical Inc. on September 17, 2018. The filing discloses the appointment of a new executive officer and details the associated compensatory arrangements.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $515,000 per year.
- Target Bonus: 50% of base salary (subject to performance goals).
- Sign-on Bonus: $200,000 (one-time, subject to withholdings).
- Equity Grant: 75,000 stock options and 15,000 restricted stock units (RSUs).
- Severance: Equivalent to one year of base salary upon termination without Cause or Constructive Termination.
Material Changes
The primary material change is the appointment of Wladimir Hogenhuis, M.D., as Chief Operating Officer, effective September 28, 2018. Dr. Hogenhuis joins the company with 24 years of pharmaceutical industry experience, most recently serving in senior management roles at GlaxoSmithKline plc and Merck & Co., Inc.
Outlook, Risks, and Unusual Items
Management Commentary: The appointment is intended to strengthen the company's commercial leadership. The compensation package includes standard vesting schedules (four years for equity) and accelerated vesting provisions in the event of a "Covered Transaction" followed by termination without Cause.
Risks and Contingencies: The equity awards are subject to continued employment. The filing references an indemnification agreement to protect the executive against liabilities arising from their service.
Investor Verification Checklist
- Verify the final grant date and exercise price for the 75,000 stock options, which depend on the closing stock price on the grant date.
- Confirm the specific performance goals required to achieve the 50% target bonus.
- Review the full text of the Offer Letter (Exhibit 10.1) for detailed definitions of "Cause" and "Constructive Termination."
- Check the company's 2014 Incentive Plan for any caps or limitations on the equity grants.